Riskpilot← Back to searchSign inGet full accessCCURE A/S
A/SActiveCVR 27648568Jægersborg Alle 164Wholesale of pharmaceutical and medical goods · NACE 4646Est. 2004— employees
Revenue 2024
DKK -43K
-65% vs 2023
EBITDA margin
100.0%
+65% vs 2023
Equity ratio
-7081602.7%
Financial strength
Net profit 2024
DKK -519K
+93% vs 2023
| Revenue | DKK -43K | -65% |
| EBITDA | DKK -43K | +65% |
| Net profit | DKK -519K | +93% |
| Total assets | DKK 187 | -99% |
| Equity | DKK -13,2M | -4% |
| Employees | — | — |
Legal name
CCURE A/S
CVR number
27648568
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
8. marts 2004
Share capital
DKK 3.666.650
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør i forening med et bestyrelsesmedlem, tre bestyrelsesmedlemmer i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at producere og sælge præfyldte injektionssprøjter.
Address
Jægersborg Alle 164
Phone
+4570264500
Email
info@ccurepharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -866 | -709 | -468 | -392 | -179 | 184 | -217 | -161 | -137 | -122 | -40 | -122 | -43 |
| Staff expenses | -30 | -2 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -896 | -711 | -468 | -392 | -179 | 184 | -217 | -188 | -165 | -122 | -40 | -122 | -43 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -150 | -0 | -0 | -0 | -0 | -0 | -0 | -7.338 | -0 |
| EBIT | -896 | -711 | -468 | -392 | -329 | 184 | -217 | -188 | -165 | -122 | -40 | -7.460 | -43 |
| Net financials | -324 | -281 | -294 | -301 | -287 | -289 | -138 | -110 | -131 | -133 | -204 | -379 | -476 |
| Profit before tax | -634 | -992 | -762 | -693 | -616 | -105 | -355 | -298 | -296 | -255 | -244 | -7.839 | -519 |
| Tax | 293 | -152 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -927 | -840 | -762 | -693 | -616 | -105 | -355 | -298 | -296 | -255 | -244 | -7.839 | -519 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 8.389 | 8.002 | 7.685 | 7.508 | 7.346 | 7.347 | 7.344 | 7.338 | 7.367 | 7.338 | 7.341 | 14 | 0 |
| Equity | -420 | -1.260 | -2.022 | -2.715 | -3.331 | -3.437 | -3.792 | -4.089 | -4.385 | -4.640 | -4.884 | -12.724 | -13.243 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 6.092 | 6.421 | 6.716 | 6.960 | 7.183 | 7.678 | 3.447 |
| Short-term debt | 8.809 | 9.261 | 9.707 | 10.223 | 10.677 | 10.783 | 5.044 | 5.006 | 5.036 | 5.018 | 5.042 | 5.060 | 9.796 |
| Total debt | 8.809 | 9.261 | 9.707 | 10.223 | 10.677 | 10.783 | 11.136 | 11.427 | 11.752 | 11.979 | 12.225 | 12.738 | 13.243 |
EBITDA margin
-4316100.0%
This company
15.8%
Market median
-27317189% vs market
20122024
Equity ratio
-7081602.7%
This company
38.2%
Market median
-18538327% vs market
20122024
Return on equity
-51877900.0%
This company
18.4%
Market median
-281945209% vs market
20122024
Net profit margin
-51877900.0%
This company
8.1%
Market median
-640468001% vs market
20122024
Asset turnover
-230.81×
This company
1.12×
Market median
-20708% vs market
20122024
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SL Audit | Audit | 2004 | — | — |
SA Chief Executive Officer | Chief Executive Officer | 2011 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2011 | — | — | |
| Board of Directors | 2010 | — | — | |
| Chairman | 2011 | — | — | |
| Chairman | 2004 | — | — | |
| Board of Directors | 2004 | — | — | |
| Board of Directors | 2008 | — | — | |
| Board of Directors | 2008 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
NM AF 18. JUNI 2009 A/S | Company | 50.0% | 50.0% | 2016 |
CHR. OLESEN A/S | Company | 33.3% | 33.3% | 2011 |
Pharmanovia A/S | Company | 50.0% | 50.0% | 2012 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Chr. Olesen Holding II A/S
CCURE A/S Board members of CCURE A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sten Lauritzen | Audit | 0 companies |
| Svend Aage Johansen | Chief Executive Officer | 0 companies |
| Mads Christian Olesen | Board of Directors | 0 companies |
| Tonni Bülow-Nielsen | Board of Directors | 0 companies |
| Bent Benny Andersen | Chairman | 0 companies |
| Ole Bjørn Jensen | Chairman | 0 companies |
| Steen Dannisgård | Board of Directors | 0 companies |
| Søren Hougaard | Board of Directors | 0 companies |
| Bent Larsen | Board of Directors | 0 companies |